Xencor Inc

Xencor is a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases. The company's proprietary XmAb technology platform enables small structural changes to antibody proteins that result in new mechanisms of therapeutic action. Xencor's wholly owned pipeline includes XmAb819 (ENPP3 x CD3) for clear cell renal cell carcinoma and other ENPP3-expressing tumors, XmAb541 (CLDN6 x CD3) in combination with XmAb808 (B7-H3 x CD28) for Claudin-6 expressing tumors, XmAb942 (anti-TL1A) for inflammatory bowel disease including ulcerative colitis, XmAb412 (TL1A x IL-23p19) for autoimmune and inflammatory diseases, plamotamab (CD20 x CD3) for rheumatoid arthritis, and XmAb657 (CD19 x CD3) for autoimmune indications including myopathies and scleroderma. The company generates revenue through collaborations, milestone payments, and royalties from partners including Alexion (Ultomiris), Zenas BioPharma (obexelimab), and Incyte. More than 20 candidates engineered with XmAb technology are in clinical development, and multiple XmAb medicines are marketed by partners. The company trades on NASDAQ under the ticker XNCR. Updated Aug 5, 2026